Results 141 to 150 of about 45,032 (221)

Cost-effectiveness of switching to S-1 after fluoropyrimidine-induced hand-foot syndrome or cardiovascular toxicity in the treatment of metastatic colorectal cancer. [PDF]

ESMO Open
van Eekelen R, Punt CJA, Kwakman JJM, Coupé VMH.   +3 more
europepmc   +1 more source

Omics Biomarkers in Precision Oncology: From the Lens of the ASCPT Biomarkers and Translational Tools and Oncology Communities

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Omics biomarkers comprise several molecular entities, including genomic, epigenomic, transcriptomic, proteomic, and metabolomic signatures. They play an essential role in oncology drug development and clinical settings by enabling personalized medicine.
Mai Mehanna, Hardik Mody, Joy C. Hsu, Julia Quintanilha, Zachary L. Taylor, Angela James, Binita Rajbanshi, Pooja Manchandani, Lakshmi Manasa Chekka   +8 more
wiley   +1 more source

Efficacy of steroid-omitting antiemetic therapy in patients with advanced pancreatic cancer receiving nano-liposomal irinotecan plus fluorouracil and leucovorin. [PDF]

Support Care Cancer
Tokito Y, Ishigaki K, Nara K, Endo G, Nishio H, Fukuda K, Suzuki T, Sato Y, Takahara N, Boku N, Fujishiro M.   +10 more
europepmc   +1 more source

Emerging Immune‐Based Therapeutic Strategies in Hepatocellular Carcinoma

Liver International, Volume 46, Issue 8, August 2026.
ABSTRACT Hepatocellular carcinoma (HCC) remains a leading cause of cancer‐related mortality worldwide despite recent advances in systemic therapy. The introduction of immune checkpoint inhibitors has substantially expanded treatment options for advanced disease; however, durable responses are observed only in a subset of patients.
Janine Kah, Werner Dammermann, Stefan Lueth   +2 more
wiley   +1 more source

NALIRIFOX versus liposomal irinotecan plus fluorouracil/leucovorin as the second-line chemotherapy in gemcitabine refractory pancreatic adenocarcinoma: a real-world study. [PDF]

Ther Adv Med Oncol
Wong WZ, Chiang NJ, Lee KC, Yu HY, Tsai CJ, Hsu SJ, Lee PC, Chen MH, Huang HC, Li CP, Luo JC, Lee FY.   +11 more
europepmc   +1 more source

Predictors of prolonged progression-free survival in patients with unresectable or recurrent pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid (NAPOLEON-2 study). [PDF]

Ther Adv Med Oncol
Kawaguchi Y, Hayashi K, Shimokawa M, Otsuka T, Nakazawa J, Shimokawa H, Shinohara Y, Koga F, Oza N, Oda H, Takeshita S, Arima S, Arita S, Nishikawa K, Otsu S, Taguchi H, Jikuya K, Sakai T, Ueda Y, Sakae T, Araki N, Sawase H, Ide Y, Kawahira M, Nio K, Shirakawa T, Mizuta T, Mitsugi K.   +27 more
europepmc   +1 more source

Pancreatic Cancer—Advances in the Last 50 Years

World Journal of Surgery, Volume 50, Issue 8, Page 2106-2115, August 2026.
S. George Barreto, Anirban Maitra, Eileen M. O'Reilly, Dushyant Sahani, Richard Zheng, Charles J. Yeo   +5 more
wiley   +1 more source

The Early Safety Signal of Sacituzumab Govitecan-Related Toxicity and the <i>UGT1A1*28</i> Genotype in Metastatic Breast Cancer: A Real-World Preliminary Report. [PDF]

J Clin Med
Martínez-Pérez M, Nieto-Sánchez MT, Díaz-Villamarín X, Torres-García A, Fernández-Varón E, Prados-Carmona A, Legerén M, Cabeza-Barrera J, Blancas I, Morón R.   +9 more
europepmc   +1 more source

Molecular Determinants of Response and Rational Drug Combinations for Antibody-Drug Conjugates (ADCs) with Topoisomerase I (TOP1) Inhibitor Payloads. [PDF]

J Mol Biol
Pommier Y.
europepmc   +1 more source

Phase II study of FOLFIRI with low-dose irinotecan plus ramucirumab as second-line treatment in Japanese patients with metastatic colorectal cancer (study rindo). [PDF]

Jpn J Clin Oncol
Hattori N, Nakayama G, Umeda S, Kishida T, Takeda S, Ezaka K, Tsutsuyama M, Sakai M, Hattori M, Ito T, Kanda M, Tanaka C, Murotani K, Ando M, Kodera Y.   +14 more
europepmc   +1 more source